Mark F. van Delft

6.9k citations

30 papers · 4.2k indexed · 3 hit papers · h-index 18

Co-authors: David C.S. Huang Peter E. Czabotar Jerry M. Adams Simon N. Willis W. Douglas Fairlie Erinna F. Lee Catherine L. Day Andreas Strasser
Topics: Cell death mechanisms and regulation (16 papers)RNA Interference and Gene Delivery (6 papers)Ubiquitin and proteasome pathways (5 papers)
Cited by: Immunology Molecular Biology Oncology
Journals: Science Cell Proceedings of the National Academy of Sciences
Partner nations: Australia Canada United States

In The Last Decade

Mark F. van Delft

30 papers receiving 4.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized

2006 1.0k citations Mark F. van Delft, Andrew H. Wei et al. Cancer Cell profile →
Apoptosis Initiated When BH3 Ligands Engage Multiple Bcl-2 Homologs, Not Bax or Bak

2007 883 citations Simon N. Willis, Jamie I. Fletcher et al. Science profile →
Apoptotic Caspases Suppress mtDNA-Induced STING-Mediated Type I IFN Production

2014 741 citations Donald Metcalf, Marco J. Herold et al. profile →

Peers

Countries citing papers authored by Mark F. van Delft

Since Specialization

Citations

This map shows the geographic impact of Mark F. van Delft's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark F. van Delft with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark F. van Delft more than expected).

Fields of papers citing papers by Mark F. van Delft

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark F. van Delft. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark F. van Delft. The network helps show where Mark F. van Delft may publish in the future.

Co-authorship network of co-authors of Mark F. van Delft

This figure shows the co-authorship network connecting the top 25 collaborators of Mark F. van Delft. A scholar is included among the top collaborators of Mark F. van Delft based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark F. van Delft. Mark F. van Delft is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Key residues in the VDAC2-BAK complex can be targeted to modulate apoptosis 2024 ·PLoS Biology ·(unknown),Mark F. van Delft,Xiang Li,(unknown),Brian J. Smith,David C.S. Huang,Guillaume Lessène,(unknown),(unknown),(unknown),Nicholas A. Smith,Richard W. Birkinshaw,Peter E. Czabotar,Grant Dewson	2
2	Improved drug target deconvolution with PISA‐DIA using an extended, overlapping temperature gradient 2024 ·PROTEOMICS ·(unknown),Jumana M. Yousef,Subash Adhikari,(unknown),(unknown),Mark F. van Delft,Guillaume Lessène,Jerzy M. Dziekan,Andrew I. Webb,Laura F. Dagley	1
3	Mitochondrial E3 ubiquitin ligase MARCHF5 controls BAK apoptotic activity independently of BH3-only proteins 2022 ·Cell Death and Differentiation ·(unknown),Hui San Chin,Boris Reljić,Tirta M. Djajawi,Iris K. L. Tan,Jianan Gong,David A. Stroud,David C.S. Huang,Mark F. van Delft,Grant Dewson	12
4	The Lck inhibitor, AMG-47a, blocks necroptosis and implicates RIPK1 in signalling downstream of MLKL 2022 ·Cell Death and Disease ·Annette V. Jacobsen,(unknown),Kym N. Lowes,Amanda E. Au,Ying Zhang,Nima Etemadi,Cheree Fitzgibbon,Wilhelmus J. A. Kersten,André L. Samson,Mark F. van Delft,David C.S. Huang,Hélène Jousset Sabroux,Guillaume Lessène,John Silke,James M. Murphy	14
5	Too much death can kill you: inhibiting intrinsic apoptosis to treat disease 2021 ·The EMBO Journal ·(unknown),Mark F. van Delft,Grant Dewson	45
6	The transcription factor IRF4 represses proapoptotic BMF and BIM to licence multiple myeloma survival 2020 ·Leukemia ·Pasquale L. Fedele,Yang Liao,Jianan Gong,Yuan Yao,Mark F. van Delft,Michael Löw,Lin Tai,Marco J. Herold,Jacob T. Jackson,Charis E. Teh,Tania Tan,Lorraine A. O’Reilly,Julie Tellier,George Grigoriadis,David C.S. Huang,Wei Shi,Stephen L. Nutt,Simon N. Willis	21
7	MARCH5 requires MTCH2 to coordinate proteasomal turnover of the MCL1:NOXA complex 2020 ·Cell Death and Differentiation ·Tirta M. Djajawi,Lei Liu,Jianan Gong,(unknown),Mingjie Luo,Zhen Xu,Toru Okamoto,Melissa Call,David C.S. Huang,Mark F. van Delft	33
8	BAK/BAX-Mediated Apoptosis Is a Myc-Induced Roadblock to Reprogramming 2018 ·Stem Cell Reports ·(unknown),Minna‐Liisa Änkö,(unknown),Ian J. Majewski,(unknown),Jaber Firas,David C.S. Huang,Mark F. van Delft,Joan K. Heath	11
9	Conversion of Bim-BH3 from Activator to Inhibitor of Bak through Structure-Based Design 2017 ·Molecular Cell ·Jason M. Brouwer,Ping Lan,Angus D. Cowan,Jonathan P. Bernardini,Richard W. Birkinshaw,Mark F. van Delft,Brad E. Sleebs,A.Y. Robin,Ahmad Z. Wardak,Iris K. L. Tan,Boris Reljić,Erinna F. Lee,W. Douglas Fairlie,Melissa Call,Brian J. Smith,Grant Dewson,Guillaume Lessène,Peter M. Colman,Peter E. Czabotar	52
10	HSP90 activity is required for MLKL oligomerisation and membrane translocation and the induction of necroptotic cell death 2016 ·Cell Death and Disease ·Annette V. Jacobsen,Kym N. Lowes,Maria C. Tanzer,Isabelle S. Lucet,Joanne M. Hildebrand,Emma J. Petrie,Mark F. van Delft,Zikou Liu,Stephanie A. Conos,Jian‐Guo Zhang,David C.S. Huang,John Silke,Guillaume Lessène,James M. Murphy	131
11	Enhanced stability of Mcl1, a prosurvival Bcl2 relative, blunts stress-induced apoptosis, causes male sterility, and promotes tumorigenesis 2013 ·Proceedings of the National Academy of Sciences ·Toru Okamoto,Leigh Coultas,Donald Metcalf,Mark F. van Delft,Stefan Glaser,(unknown),Andreas Strasser,Philippe Bouillet,Jerry M. Adams,David C.S. Huang	37
12	Apoptosis and non-inflammatory phagocytosis can be induced by mitochondrial damage without caspases 2009 ·Cell Death and Differentiation ·Mark F. van Delft,Dean P. Smith,Mireille H. Lahoud,David C.S. Huang,Jerry M. Adams	33
13	A Structural Viral Mimic of Prosurvival Bcl-2: A Pivotal Role for Sequestering Proapoptotic Bax and Bak 2007 ·Molecular Cell ·Marc Kvansakul,Mark F. van Delft,Erinna F. Lee,Jacqueline M. Gulbis,W. Douglas Fairlie,David C.S. Huang,Peter M. Colman	112
14	Apoptosis Initiated When BH3 Ligands Engage Multiple Bcl-2 Homologs, Not Bax or Bakbreakdown → 2007 ·Science ·Simon N. Willis,Jamie I. Fletcher,Thomas Kaufmann,Mark F. van Delft,Lin Chen,Peter E. Czabotar,(unknown),Erinna F. Lee,W. Douglas Fairlie,Philippe Bouillet,Andreas Strasser,Ruth M. Kluck,Jerry M. Adams,David C.S. Huang	883
15	How the Bcl-2 family of proteins interact to regulate apoptosis 2006 ·Cell Research ·Mark F. van Delft,David C.S. Huang	282
16	The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralizedbreakdown → 2006 ·Cancer Cell ·Mark F. van Delft,Andrew H. Wei,Kylie D. Mason,Cassandra J. Vandenberg,Lin Chen,Peter E. Czabotar,Simon N. Willis,Clare L. Scott,Catherine L. Day,Suzanne Cory,Jerry M. Adams,Andrew W. Roberts,David C.S. Huang	1008
17	Ataxin-7 Can Export from the Nucleus via a Conserved Exportin-dependent Signal 2005 ·Journal of Biological Chemistry ·Jillian Taylor,(unknown),Jianrun Xia,Mark F. van Delft,(unknown),Lisa Ellerby,Albert R. La Spada,Ray Truant	34
18	Bcl-2–regulated apoptosis and cytochrome c release can occur independently of both caspase-2 and caspase-9 2004 ·The Journal of Cell Biology ·Vanessa S. Marsden,Paul G. Ekert,Mark F. van Delft,David L. Vaux,Jerry M. Adams,Andreas Strasser	84
19	RNA association and nucleocytoplasmic shuttling by ataxin-1 2004 ·Journal of Cell Science ·(unknown),Mark F. van Delft,Deborah Pinchev,(unknown),(unknown),Harry T. Orr,Ray Truant	88
20	Peroxisome Proliferator-activated Receptor γ Ligands Differentially Modulate Muscle Cell Differentiation and MyoD Gene Expression via Peroxisome Proliferator-activated Receptor γ-dependent and -independent Pathways 2001 ·Journal of Biological Chemistry ·John G. Hunter,Mark F. van Delft,Richard A. Rachubinski,John P. Capone	38

About Mark F. van Delft

Mark F. van Delft is a scholar working on Molecular Biology, Hematology and Immunology, having authored 30 papers that have together received 4.2k indexed citations. Recurring topics across this work include Cell death mechanisms and regulation (16 papers), RNA Interference and Gene Delivery (6 papers) and Ubiquitin and proteasome pathways (5 papers). The work is most often cited by research in Immunology (1.1k citations), Molecular Biology (3.4k citations) and Oncology (890 citations). Mark F. van Delft has collaborated with scholars based in Australia, Canada and United States. Frequent co-authors include David C.S. Huang, Peter E. Czabotar, Jerry M. Adams, Simon N. Willis, W. Douglas Fairlie, Erinna F. Lee, Catherine L. Day, Andreas Strasser, Philippe Bouillet and Cassandra J. Vandenberg. Their work appears in journals such as Science, Cell and Proceedings of the National Academy of Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact